Veracyte Inc (VCYT) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally.

Total Assets Chart for Veracyte Inc

Veracyte Inc (VCYT) total assets for FY2025 were USD 1.4B, a 8.2% change from FY2024. Veracyte Inc's total assets grew from USD 10.5M in 2011 to USD 1.4B in 2025 (13353.4% over 14 years). Total assets compound annual growth rate: 5-year CAGR of 25.2%, 10-year CAGR of 34.0%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$3.47B
Implied Share Price
$43.12
Enterprise Value
$3.08B
Revenue (TTM)
$561.90M
EBITDA
$113.52M
Profit Margin
20.37%
Trailing P/E
30.80
Forward P/E
23.58
Price/Book (MRQ)
2.54
Price/Sales (TTM)
6.17
EV/EBITDA
22.51
EV/Revenue
5.48
Dividend Yield
—
Book Value
$17.28
Free Cash Flow (FY2025)
$126.63M
Free Cash Flow Yield
3.65%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.